September 4th 2024
Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory disease and long-term follow-up of pivotal trials.
Treatment Challenges Beyond Second-Line in Relapsed/Refractory Follicular Lymphoma
April 22nd 2021The challenges faced in treating patients beyond second-line treatment are addressed. Kami Maddocks, MD, reviews the frequency of patients who require third- and fourth-line treatment, in addition to the factors that affect treatment decisions in later lines of therapy.
Watch
FDA Approves Axi-Cel for Relapsed/Refractory Follicular Lymphoma in Third-Line or Beyond
March 6th 2021The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
Read More
Study of Betalutin in R/R Follicular Lymphoma Shows Good Progress Despite COVID-19
February 22nd 2021Enrollment of patients with relapsed or refractory follicular lymphoma in a phase 2 LYMRIT 37-01 PARADIGME study of third-line Lu lilotomab satetraxetan has increased accrual to 2-5 patients per month.
Read More
Tisagenlecleucel Leads to High CR Rate in Heavily Pretreated, R/R Follicular Lymphoma
February 22nd 2021Tisagenlecleucel induced a significant number of complete responses in patients with relapsed or refractory follicular lymphoma, meeting the primary end point of the phase 2 ELARA trial as of the interim analysis of the study.
Read More
Precision Medicine Shapes the Future of Follicular Lymphoma Management
February 19th 2021In an interview with Targeted Oncology, Carla Casulo, MD, discussed the modern management of patients with relapsed/refractory follicular lymphoma. She also explained how ongoing research may shape the future of the field.
Read More
Tisagenlecleucel Safe and Effective in Relapsed/Refractory Follicular Lymphoma
January 13th 2021Anti-CD19 chimeric antigen receptor T-cell therapy with tisagenlecleucel has shown efficacy for the treatment of patients with extensively treated and refractory follicular lymphoma, according to preliminary phase 2 data from the ELARA clinical trial.
Read More
Rituximab Plus Anthracycline-Based Chemotherapy Prolongs Survival Long-Term in Follicular Lymphoma
January 8th 2021Rituximab added to standard anthracycline-based chemotherapy demonstrated significant improvements in progression-free survival as well as overall survival as treatment of patients with follicular lymphoma, according to 35-year follow-up results of patients treated through the Nebraska Lymphoma Study Group.
Read More
Broad Spectrum of Upfront Therapies Available for Follicular Lymphoma
December 10th 2020In an interview with Targeted Oncology, John M. Burke, MD, discussed the current treatment paradigm for patients with follicular lymphoma and reviewed the factors he considers when making treatment decisions for this population.
Read More
Mosunetuzumab Elicits High and Durable Responses in Subgroups of Patients With FL
December 8th 2020A phase clinical trial has demonstrated that administering a mosunetuzumab fixed-duration leads to high, durable, and consistent responses in patients with follicular lymphoma across multiple subgroups. Data from the study were presented during the virtual 2020 American Society of Hematology Annual Meeting.
Read More
R-CHOP Found Superior in Grade 3A, 1-2-3A Follicular Lymphoma
November 13th 2020A new retrospective analysis has suggested that the R-CHOP chemotherapy regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone leads to superior outcomes compared to rituximab plus bendamustine in patients with grade 3A follicular lymphoma.
Read More
In Low-Grade Follicular Lymphoma, Expert Weighs Frontline Options
November 4th 2020A general framework can be utilized to guide treatment decision in patients with follicular lymphoma, according to John P. Leonard, MD. During a presentation for the 38th Annual Chemotherapy Foundation Symposium, Leonard also explained that bulk of disease, comorbidities, and toxicity, among others are all factors that impact treatment decisions.
Read More
Copanlisib Combo Prolongs PFS in Phase 3 Study of Indolent Non-Hodgkin Lymphoma
October 15th 2020The primary end point of prolonged progression-free survival in the phase 3 CHRONOS-3 study was met with copanlisib in combination with rituximab as treatment of patients with indolent non-Hodgkin lymphoma.
Read More
FDA to Review sBLA for Axi-Cel in R/R Follicular Lymphoma and Marginal Zone Lymphoma
September 5th 2020The FDA has accepted a supplemental Biologics License Application for axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma after 2 or more prior lines of systemic therapy.
Read More
The question of whether patients with asymptomatic advanced-stage follicular lymphoma should undergo watch-and-wait observation or start treatment immediately was addressed at the 2020 Debates and Didactics in Hematology and Oncology during a debate between Jean Louise Koff, MD, MS, and James O. Armitage, MD.
Read More
Lenalidomide/Rituximab Induction as Effective as Rituximab Plus Chemo in Follicular Lymphoma Subset
August 4th 2020Lenalidomide in combination with rituximab (Rituxan, R2) induction has the ability to achieve high rates of complete molecular response (CMR), similar to rituximab plus chemotherapy, when used as frontline therapy in patients with follicular lymphoma (FL), according to results from the phase 3 RELEVANCE trial (NCT01650701).
Read More
Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point
August 4th 2020Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.
Read More
Tazemetostat Approval Addresses Unmet Need in Relapsed/Refractory Follicular Lymphoma
June 26th 2020In an interview with Targeted Oncology, John P. Leonard, MD, discussed the results of the phase 2 study of tazemetostat, the drug approval for relapsed/refractory follicular lymphoma, and the role of tazemetostat in the community setting.
Read More
FDA Approves Tazemetostat for Relapsed/Refractory Follicular Lymphoma
June 18th 2020"The durable responses observed with this drug are notable in the context of the safety profile and route of oral, at-home administration, and will offer an important new option for physicians as we care for patients with relapsed/refractory follicular lymphoma."
Read More